Without a common understanding of terminology, principles, or application of risk management concepts, the pharmaceutical industry is at risk for delays in product introductions, inefficient use of resources, and most importantly, unsafe items being allowed on the market. The biopharmaceutical industry challenge is to streamline the regulatory compliance process with ICH Q9 and Q10 regulations and improving conformance to regulations and standards, yet at the same time reducing the cost of compliance activities.
This is a password protected area. If you already have an existing account please login now.
If you would like to sign-up for an account, please click the register now button.
Please note that Dyadem only accepts corporate email addresses.
Register Now